| DC12381 |
DLin-KC2-DMA
Featured
|
DLin-KC2-DMA is a highly potent ionizable lipid used in the formulation of lipid nanoparticles (LNPs) for the delivery of siRNA. It represents a significant advancement over earlier generations of lipids, such as DLin-DMA, due to its dramatically improved gene silencing efficiency. |
|
| DC11486 |
D-Luciferin (potassium salt)
Featured
|
D-Luciferin is a chemiluminescent substrate of firefly luciferase. |
|
| DC9287 |
D-Luciferin
Featured
|
D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications.
Cas: 2591-17-5 |
|
| DC11426 |
DM1-PEG4-DBCO
Featured
|
DM1-(PEG)4-DBCO (DBCO-PEG4-DM1) is made by DM1 conjugated to DBCO-(PEG)4 linker.DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent. |
|
| DC8539 |
DM1-SMCC
Featured
|
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. |
|
| DC11396 |
DM1-SMe
Featured
|
DM1-SMe is a potent maytansinoid microtubular inhibitor and an unconjugated DM1 as a mixed disulfide with thiomethane to cap its sulfhydryl group. |
|
| DC9401 |
DMAT(CK2 Inhibitor)
Featured
|
DMAT is a potent and specific CK2 inhibitor with an IC50 of 0.13 uM. |
|
| DC7643 |
DMH1
Featured
|
DMH1 is a selective BMP receptor inhibitor with IC50 of 107.9 nM for ALK2, exhibiting no inhibition on AMPK, ALK5, KDR (VEGFR-2) or PDGFR. |
|
| DC7403 |
Dimethyloxaloylglycine(DMOG)
Featured
|
DMOG is a cell permeable prolyl-4-hydroxylase inhibitor, which upregulates HIF (hypoxia-inducible factor). |
|
| DC9434 |
DMP 777 |
DMP 777(L-694458) is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.
|
|
| DC20600 |
DM-PIT-1
Featured
|
DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively. |
|
| DC12079 |
DMU2105 |
DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10, 742 nM for CYP1B1 and CYP1A1, respectively. |
|
| DC11473 |
DMU-2105(CYP1B1 inhibitor 7k)
Featured
|
DMU-2105(CYP1B1 inhibitor 7k) is a potent and specific CYP1B1 inhibitor. |
|
| DC22291 |
DMU-212（resveratrol analog）
Featured
|
DMU-212, a methoxylated resveratrol analog, has significant anticancer activity, and selectively targets tumor cells. |
|
| DC22307 |
DMX-5804
Featured
|
DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). |
|
| DC7404 |
DMXAA
Featured
|
DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3. |
|
| DC20959 |
DNDI-8219 |
DNDI-8219 is a novel potent, orally active antileishmanial agent with IC50 of 0.19 uM against Leishmania donovani (L. don). |
|
| DC23671 |
DNMDP |
DNMDP is a potent and selective cancer cell cytotoxic agent that binds to PDE3A, promotes an interaction between PDE3A and Schlafen 12 (SLFN12). |
|
| DC11337 |
MMP Substrate II Control |
Dnp-GPLG is a peptide for use as a negative control for activity of matrix metalloproteinases (MMPs) that cleave peptides containing the sequence Dnp-GPLG. |
|
| DC11342 |
MMP-1 Fluorogenic Substrate III |
Dnp-P-Cha-Abu-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9. |
|
| DC11348 |
MMP-1/MMP-9 Fluorogenic Substrate
Featured
|
Dnp-P-Cha-G-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9 |
|
| DC11351 |
MMP-1 Fluorogenic Substrate I
Featured
|
Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8. |
|
| DC11339 |
MMP-8/MMP-26 Fluorogenic Substrate
Featured
|
Dnp-PLAYWAR is a fluorogenic substrate for matrix metalloproteinase-8 (MMP-8) and MMP-26.The activity of MMP-8 and MMP-26 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitro |
|
| DC11347 |
MMP-1 Substrate II
Featured
|
Dnp-PLG-Cys(Me)-HA-DArg-NH2 is a peptide substrate for matrix metalloproteinase-1 (MMP-1).It has an improved kcat/Km ratio compared with the MMP-1 flurogenic substrate Dnp-PLGLWA-DArg-NH2. |
.png)
|
| DC11344 |
MMP-2/MMP-9 Fluorogenic Substrate I |
Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitroph |
|
| DC11345 |
MMP-7 Fluorogenic Substrate |
Dnp-RPLALWRS is a fluorogenic substrate for matrix metalloproteinase-7 (MMP-7).The activity of MMP-7 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group. |
|
| DC10673 |
DNQX disodium salt
Featured
|
DNQX is a elective non-NMDA antagonist |
|
| DC10672 |
DNQX
Featured
|
DNQX is a elective non-NMDA antagonist |
|
| DC21509 |
DNS-pE |
DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
| DC20364 |
DNS-pE2 |
DNS-pE2 is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
